Cardiometabolic Disease
Conditions
Interventions
PCSK9 group: Addition of PCSK9 inhibitor to standard therapy:None
Control group: Continuation of standard lipid-lowering therapy (statin+/- ezetimibe):None
Sponsors
The First Hospital of Qinhuangdao
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. Confirmed diagnosis of at least one atherosclerotic cardiovascular disease (coronary heart disease, ischemic stroke/TIA, or peripheral artery disease); 3. Meet CMD criteria with concomitant diabetes, obesity, metabolic syndrome, or dyslipidemia; 4. Receiving stable lipid-lowering therapy but with uncontrolled lipid levels, planning to use PCSK9 inhibitors or continue standard therapy; 5. Voluntarily participating in the study and having signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. Has received PCSK9 inhibitor treatment within the past 2 months; 2. Severe hepatic or renal insufficiency; 3. Active malignancy or expected survival time < 1 year; 4. Pregnant or lactating women; 5. Inability to complete follow-up or incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C goal attainment rate at 12 months;LDL-C goal attainment rate at 24 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-HDL-C goal attainment rate;Incidence of major adverse cardiovascular events;Hospitalization rate; | — |
Countries
China
Contacts
Public ContactMa Lixiang
The First Hospital of Qinhuangdao
Outcome results
None listed